Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma

BACKGROUND: The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic agents has shown promising efficacy in unresectable hepatocellular carcinoma (HCC), but until now no clinical prognostic models or predictive biomarkers have been established. METHODS: From 2016 to 2021, a total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomi, Sun, Wei, Ding, Xiaoyan, Li, Wei, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751696/
https://www.ncbi.nlm.nih.gov/pubmed/36532029
http://dx.doi.org/10.3389/fimmu.2022.1060051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751696/
https://www.ncbi.nlm.nih.gov/pubmed/36532029
http://dx.doi.org/10.3389/fimmu.2022.1060051

Ejemplares similares